The University of Queensland (UQ) has announced a wireless neuro-stimulator to treat neurological disorders such as Parkinson’s, chronic depression and other psychiatric conditions.

The university’s Queensland Brain Institute (QBI) collaborated with Neurosciences Queensland and Abbott Neuromodulation to develop the remote care platform.

It allows patients to access treatment from anywhere in the world.

Using the new integrated digital platform, clinicians will be able to monitor patients remotely, treat symptoms in real-time and adjust the device for treatment.

The wireless platform would help support data-driven clinical decisions and also allow more personalised treatment.

Queensland Brain Institute professor Peter Silburn said: “We have shown that it is possible to minimise disruption to patients’ and carers’ lifestyles by increasing accessibility to the service, saving time and money.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“There are no cures for many of these conditions, which often require life-long treatment and care, so for those people the device would be a game-changer.”

Launched last October in Australia, the digital health platform has now received CE-Mark as well as US Food and Drug Administration (FDA) approval.

UQ noted that the research team commenced working on the new platform prior to the Covid-19 pandemic, which elevated the need for remote care platforms, mainly for the treatment of older people and patients in remote areas.

They also stated that the new technology can be adapted for other conditions in the future.